The scope of the report is to highlight and gauge existing technologies in the production of therapeutic mAbs. The report also discusses key insights on interchangeability and substitution of therapeutic antibodies and biosimilars.
Further, there is also an assessment of the current drivers and restraints that affect the uptake of biosimilars.
The report answers key questions that are paramount for understanding the ... Read more
Generic drugs market was worth USD 290.83 billion in 2018 and is expected to reach USD 412.50 billion by 2023 with a CAGR of 7.24%. A Generic drug is a pharmaceutical drug, which has the equal chemical substance as the first developed drug. Generic drugs are allowed for profits after patent(s) on unique drug expired. Because the active chemical substance is the same, the medical profile of generics is thought about as being identical in ... Read more
Bharat Book Bureau Provides the Trending Market Research Report on "US Biosimilars Market , Dosage, Price & Clinical Pipeline Outlook 2025” under Life Sciences Category. The report offers a collection of superior market research, market analysis, and competitive intelligence and industry reports.
Report Highlights:
- US Biosimilar Market Current Scenario
- US Biosimilars Clinical Pipeline by Company, Indication ... Read more
On a global scale, the Biosimilars market is currently showing significant development. The Biosimilars market is experiencing a growth velocity due to the new product prototype versions, world market dynamics, topological variations, economic statistics, product demands and sales that is taking place in the present day. The ... Read more
Biosimilars are biopharmaceutical drugs that are highly similar to Food and Drug Administration (FDA) approved biological drugs, known as reference product biologics. Biosimilars provide effective therapeutic treatments for various diseases at a lower cost as compared to their reference biologics. The growing prevalence of chronic diseases and rising healthcare expenditure are fueling the demand for affordable biosimilars globally. The global biosimilars market is estimated to be valued at ... Read more
Biosimilars are biopharmaceutical drugs which are similar to previously marketed biological drugs known as reference biologics. Biosimilars help provide cost-effective treatment options for chronic diseases such as cancer, diabetes, and autoimmune diseases. Biosimilars offer savings of 30-50% in terms of cost as compared to their reference biologics.
The global Biosimilars Market is estimated to be valued at US$ 33.87 Mn in 2024 and is expected to exhibit a ... Read more
The healthcare industry has seen tremendous improvements over the past few decades thanks to advancements in technology and research. However, one area that still posed challenges was the high cost of biologics which are drugs produced from living organisms. Developing and manufacturing biologics requires complex technology and extensive clinical research which drives up costs making these life-saving drugs out of reach for many patients.
Humira has been a blockbuster drug since its approval in 2002. As Humira goes off-patent, biosimilars are now entering the market, offering more affordable treatment options for patients.
What is Humira?
Humira (adalimumab) is a biologic drug developed and marketed by AbbVie for the treatment of several autoimmune diseases such as rheumatoid arthritis, Crohn's disease, psoriasis etc. It is a monoclonal antibody and works by blocking tumor necrosis factor- ... Read more
